⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GMAB News
Genmab A/S ADS
CAR T-cell Therapy for NHL Clinical Trial Landscape Expands: Over 70 Companies Advancing Next-Generation Therapies | DelveInsight
globenewswire.com
NVS
ALLO
LEGN
CBIO
MBIO
CRSP
INCY
IMPP
SANA
VOR
CARG
AUTL
ARCL
LYEL
PRE
BEAM
CART
TAK
AZN
MRK
BMY
GEN
DGX
GMAB
ABBV
RLGT
CRGO
JNJ
GILD
JAZZ
SYBX
CASI
ATRA
SHEN
BIIB
VREX
Capital Increase in Genmab as a Result of Employee Warrant Exercise
globenewswire.com
GMAB
Notice to Convene an Extraordinary General Meeting of Genmab A/S
globenewswire.com
GMAB
Genmab to Participate in Upcoming Investor Conferences
globenewswire.com
GMAB
Capital Increase in Genmab as a Result of Employee Warrant Exercise
globenewswire.com
GMAB
Genmab Announces Financial Results for the First Half of 2026
globenewswire.com
GMAB
Genmab Announces Financial Results for the First Half of 2026
globenewswire.com
GMAB
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
globenewswire.com
GMAB
ABBV
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
businesswire.com
GMAB
ABBV
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
globenewswire.com
GMAB
ABBV